03:19:30 Europe / Stockholm

Prenumeration

2024-01-25 10:30:00
  • Limited effect on short-term earnings, higher perceived risk
  • Bioextrax signs MoU with Chematur Engineering
  • We have adjusted the fair value to SEK 7.60 (10.50) per share

In September 2023, an American start-up company extended the license agreement with Bioextrax regarding production of PHA. In January 2024, the American company had to terminate the contract due to financial issues. Hence, our model suggests a fair value of SEK 7.60 per share.

The initial research report is available here.